Skip to main content
ECCO News 2024/4

Volume 19, Issue 4

Featured Articles

images/publications/news/2025/issue-2/Meet%20the%20Reps_logo_new%20blue-01.png#joomlaImage://local-images/publications/news/2025/issue-2/Meet the Reps_logo_new blue-01.png?width=1215&height=1215

Meet the Reps: Germany - Interview with Dominik Bettenworth and Raja Atreya

images/portraits/edouard-louis-gb.jpg#joomlaImage://local-images/portraits/edouard-louis-gb.jpg?width=1000&height=1000

Interview with ECCO Secretary Edouard Louis

images/publications/news/2024/issue-4/letter-from-ecco-president-volumne-19-issue-4.jpg#joomlaImage://local-images/publications/news/2024/issue-4/letter-from-ecco-president-volumne-19-issue-4.jpg?width=200&height=200

Letter from the ECCO President

ECCO’25: Come to Berlin!
19 December 2024

Meet the JCC Authors: Podcast with Tian Hong Wu

Spyros Siakavellas, ECCO News Associate Editor
Spyros Siakavellas, ECCO News Associate Editor
Dear ECCO friends and family, welcome to this interesting discussion with Dr. Tian Hong Wu first author of the exciting paper “Natural History of Crohn’s Disease Leading to Intestinal Failure: A Longitudinal Cohort Study from 1973 to 2018”.
Continue reading
19 December 2024

Y-ECCO Literature Review: Megha Bhandari

Megha Bhandari
Artificial intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis
Iacucci and colleagues explored the application of machine learning in diagnosing histological remission and predicting clinical outcomes in UC patients.
Continue reading
19 December 2024

Y-ECCO Literature Review: Gaurav Nigam

Gaurav Nigam
Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease
Wijnands and colleagues sought to develop and validate a dynamic prediction model for advanced colorectal neoplasia (aCRN), including high-grade dysplasia and CRC, in IBD patients.
Continue reading
19 December 2024

Y-ECCO Literature Review: Tommaso Innocenti

Tommaso Innocenti
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial
Lindsay and colleagues sought to conduct the ASTIClite trial, to investigate the safety and efficacy of HSCT with a reduced intensity (potentially safer) conditioning regimen and a more traditional (and potentially more achievable) primary endpoint.
Continue reading
19 December 2024

Y-ECCO Members’ Address

Bram Verstockt, GuiCom Member
Bram Verstockt, Y-ECCO Committee Chair
As I will be stepping down as Y-ECCO Chair at the upcoming ECCO Congress in Berlin, I want to take this final “Member’s Address” as an opportunity to thank each of you for your commitment to our shared mission of supporting those living with Inflammatory Bowel Disease.
Continue reading

Search ECCO News